225 related articles for article (PubMed ID: 6980005)
1. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
Smith CM; Henderson JF
Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
[TBL] [Abstract][Full Text] [Related]
2. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
[TBL] [Abstract][Full Text] [Related]
3. ATP depletion as a consequence of adenosine deaminase inhibition in man.
Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
Bontemps F; Van den Berghe G
Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
[TBL] [Abstract][Full Text] [Related]
5. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
Smith CM; Belch A; Henderson JF
Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
[No Abstract] [Full Text] [Related]
6. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
[TBL] [Abstract][Full Text] [Related]
7. Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2'-deoxycoformycin, and adenosine deaminase inhibitor.
Ratech H; Thorbecke GJ; Hirschhorn R
Clin Immunol Immunopathol; 1981 Oct; 21(1):119-27. PubMed ID: 6268339
[No Abstract] [Full Text] [Related]
8. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2'-deoxycoformycin and deoxyadenosine in vitro.
Begleiter A; Pugh L; Israels LG; Johnston JB
Cancer Res; 1988 Jul; 48(14):3981-6. PubMed ID: 3260129
[TBL] [Abstract][Full Text] [Related]
9. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
Ho AD; Ganeshaguru K; Knauf W; Dietz G; Trede I; Hoffbrand AV; Hunstein W
Leuk Res; 1989; 13(4):269-78. PubMed ID: 2785618
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
Svendsen KR; Overgaard-Hansen K; Frederiksen S
Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
[TBL] [Abstract][Full Text] [Related]
11. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
Agarwal RP
Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
[No Abstract] [Full Text] [Related]
12. Role of glycolysis in deoxyadenosine induced ATP depletion and dATP accumulation in red cells.
Koller CA; Orringer EP; Berkowitz LR; Mulhern AT
Prog Clin Biol Res; 1984; 165():227-39. PubMed ID: 6334314
[No Abstract] [Full Text] [Related]
13. dATP accumulation and ATP depletion in platelets in adenosine deaminase deficiency: significance for the immune response?
Simmonds HA; Goday A; Morris GS; Fairbanks LD; Levinsky RJ
Biosci Rep; 1984 Oct; 4(10):809-18. PubMed ID: 6335053
[TBL] [Abstract][Full Text] [Related]
14. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
[No Abstract] [Full Text] [Related]
15. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
Bagnara AS; Hershfield MS
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
[No Abstract] [Full Text] [Related]
17. Effect of 2'-deoxycoformycin on the inhibition of deoxyribonucleic acid synthesis by 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
Shewach DS; Plunkett W
Biochem Pharmacol; 1982 Jun; 31(11):2103-9. PubMed ID: 6180754
[No Abstract] [Full Text] [Related]
18. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
19. Hypnotic effects of deoxycorformycin in rats.
Radulovacki M; Virus RM; Djuricic-Nedelson M; Green RD
Brain Res; 1983 Jul; 271(2):392-5. PubMed ID: 6604561
[TBL] [Abstract][Full Text] [Related]
20. Selective immunotoxic effects in mice treated with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Luebke RW; Lawson LD; Rogers RR; Riddle MM; Rowe DG; Smialowicz RJ
Immunopharmacology; 1987 Feb; 13(1):25-35. PubMed ID: 2952620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
